Copyright
©The Author(s) 2020.
World J Clin Cases. Dec 6, 2020; 8(23): 5935-5943
Published online Dec 6, 2020. doi: 10.12998/wjcc.v8.i23.5935
Published online Dec 6, 2020. doi: 10.12998/wjcc.v8.i23.5935
CD155 expression | P value | ||
TILs phenotypes | Negative (n = 78) | Positive (n = 48) | |
CD4+ TILs, mean ± SD | 60% ± 22% | 61% ± 22% | 0.788 |
CD4+/PD-1+ TILs, mean ± SD | 21% ± 20% | 30% ± 19% | 0.004 |
CD4+/PD-1- TILs, mean ± SD | 39% ± 20% | 31% ± 19% | 0.032 |
CD8+ TILs, mean ± SD | 23% ± 13% | 24% ± 11% | 0.342 |
CD8+/PD-1+ TILs, mean ± SD | 4% ± 5% | 5% ± 5% | 0.280 |
CD8+/PD-1- TILs, mean ± SD | 19% ± 10% | 20% ± 9% | 0.437 |
- Citation: Wang RB, Li YC, Zhou Q, Lv SZ, Yuan KY, Wu JP, Zhao YJ, Song QK, Zhu B. Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment. World J Clin Cases 2020; 8(23): 5935-5943
- URL: https://www.wjgnet.com/2307-8960/full/v8/i23/5935.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i23.5935